The International Vaccine Institute (IVI) is an independent international organization originally established at the initiative of the United Nations Development Programme in 1997. Its mission is to discover, develop, and deliver safe, effective, and affordable vaccines—empowering vaccine equity, impact, and sustainability globally. IVI’s current portfolio includes vaccines in multiple stages of pre-clinical and clinical development targeting infectious diseases that significantly impact low- and middle-income countries, including cholera, typhoid fever, chikungunya, shigellosis, salmonellosis, schistosomiasis, hepatitis E, HPV- and group A strep-related diseases, and COVID-19. IVI developed the world’s first low-cost oral cholera vaccine and a new-generation typhoid conjugate vaccine, both pre-qualified by the World Health Organization (WHO). IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Bhutan, Burkina Faso, Ghana, Ethiopia, and Madagascar. 42 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, Austria, and Thailand provide state funding. For more information, please visit https://www.ivi.int.
Unlock the market timeline & signal feed
2 signals in the last 90 days.
The order this company entered each market — oldest to newest
DigitalOcean · Singapore
Novabridge Appoints Srishti Gupta as CEO
Sign up to see the full signal feed
How International Vaccine Institute (IVI)'s international expansion compares to its competitors
International Vaccine Institute (IVI)YouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 International Vaccine Institute (IVI)You | 1 | 1 | -100% | 2 | 12 |
16 roles opened in the last 90 days.
Seoul, South Korea · 3w ago
Associate Researcher (DSI_Data Management Department)
Seoul, South Korea · last mo.
Consultant (Policy & Economic Research Department)
Seoul, South Korea · last mo.
Financial Accounting & Reporting Manager (Accounting & Finance Department)
5 technologies detected across the stack.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
3 mentions in the last 90 days.
GC Labs Medical Foundation conducted training for infectious disease experts from 8 countries including Ghana, Vietnam, and Egypt through KOFIH's fellowship program, covering diagnostic testing and infection response systems.
SK bioscience will lead the Gates Foundation-funded ROTOR project, developing an AI-powered platform with PATH and Slalom to optimize vaccine clinical development decisions, initially focusing on rotavirus vaccines for LMICs.
Novabridge Biopharmaceuticals appoints Dr. Srishti Gupta as CEO effective July 1, 2026, replacing Dr. Sean Fu. Gupta brings over 20 years of leadership experience to advance Givastomig and VIS-101 toward registration.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about International Vaccine Institute (IVI)'s business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
